When was RecBio founded?

RecBio was founded in 2012 and raised its 1st funding round 7 years after it was founded.

Where is RecBio located?

RecBio is headquartered in Taizhou, China.

Who is the current CEO of RecBio?

Yong Liu of RecBio. They have also founded 1 company.

How many employees does RecBio have?

As of Jul 01, 2024, the latest employee count at RecBio is 201 - 500.

Is RecBio a funded company?

RecBio is a funded company, having raised a total of $172M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2019.

When was the latest funding round of RecBio?

RecBio's latest funding was a $***** Series B round on Dec 17, 2020, with participation from 9 investors. Its primary sector is Life Sciences Platforms and Tools. In China, the Life Sciences Platforms and Tools sector has seen $61.9M in funding in 2026 to date.

Where does RecBio rank among its competitors?

RecBio ranks 250th amongst 2309 active competitors, of which 520 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of RecBio?

RecBio's top competitors include HOOKIPA Pharma, Antheia and Transcenta. Among them, Antheia secured the most recent funding round in January, 2026.

RecBio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of vaccines to prevent infectious disease. The company's products include recombinant COVID-19 vaccine, coronary pneumonia vaccine (CHO cell) ReCOV, Human Papillomavirus Vaccine (Nine/Bivalent) to prevent HPV-induced infections, and recombinant shingles vaccine to prevent the infraction caused by the varicella-zoster virus (VZV).

Website: recbio.cn
Email ID: *****@recbio.cn

Key Metrics

Founded Year

2012

Location

Taizhou, China

Stage

Public

Total Funding

$172M in 2 rounds

Latest Funding Round

Series B, Dec 17, 2020, $*****

Investors

Legend Capital & 8 more

Ranked

250^th among 2309 active competitors

Employee Count

201 - 500 as on Jul 01, 2024

Similar Companies

HOOKIPA Pharma & 3081 more

Exit Details

Public

View RecBio's full profile

RecBio got listed on Mar 31, 2022.

Click here to take a look at RecBio's IPO in detail

RecBio has raised a total funding of $172M over 2 rounds. Its first funding round was on 2019. Its latest funding round was a Series B round on Dec 17, 2020 for $*****. 9 investors participated in its latest round. RecBio has 9 institutional investors.

Here is the list of recent funding rounds of RecBio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 17, 2020	7423804	Series B	3743073	9907876	4171376	2552135
2019	6434	Series A	7397	3350	6105	3243

Access funding benchmarks and valuations. Sign up today!

View details of RecBio's funding rounds and investors

The founders of RecBio is Yong Liu. Yong Liu is the CEO of RecBio.

Here are the details of RecBio's key team members:

Yong Liu: Founder & CEO of RecBio.

View details of RecBio's Founder profiles and Board Members

RecBio's employee count trend

RecBio has 201 - 500 employees as of Jul 24. Here is RecBio's employee count trend over the years:

Uncover RecBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RecBio include HOOKIPA Pharma, Antheia and Transcenta. Here is the list of Top 10 competitors of RecBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	70/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	68/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Tonix Pharma 2007, New York City (United States), Public	Developer of next-generation medicines for CNS and immunological disorders	$4.45M	Westwicke, Technology Partners & 2 others	66/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
6th	Axol Bioscience 2013, Cambridge (United Kingdom), Series A	Provider of human cells, reagents, and reprogramming services	$13.3M	Calculus Capital, Scottish Enterprise & 13 others	64/100
7th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
8th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
9th	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	64/100
10th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Invesco & 7 others	63/100
250th	RecBio 2012, Taizhou (China), Public	Developer of vaccines to prevent infectious disease	$172M	LYFE Capital, CoStone Capital & 7 others	44/100